Literature DB >> 1505484

Structure of human type II 5 alpha-reductase gene.

F Labrie1, Y Sugimoto, V Luu-The, J Simard, Y Lachance, D Bachvarov, G Leblanc, F Durocher, N Paquet.   

Abstract

The best known activity of steroid 5 alpha-reductase is the transformation of testosterone into dihydrotestosterone, the most potent androgen. Two types of human steroid 5 alpha-reductase cDNAs and the type I gene have previously been isolated and characterized. This report describes the isolation and characterization of the human type II 5 alpha-reductase gene, the gene most likely responsible for male pseudohermaphroditism due to 5 alpha-reductase deficiency as well as the one presumed to be involved in a major androgen-related diseases such as prostate cancer and benign prostatic hyperplasia. The type II 5 alpha-reductase gene contains five exons of 352, 164, 102, 151 and 1695 bp, respectively, which share 43.8% to 64.1% homology with exons of the corresponding type I gene. These exons are separated by four introns of greater than 29, and approximately 2.3, 2.0 and 3.0 kb. Analysis of primer extension products by polyacrylamide gel electrophoresis as well as by subcloning and sequencing reveals a start site located 71 nucleotides upstream the ATG initiating codon.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1505484     DOI: 10.1210/endo.131.3.1505484

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  19 in total

1.  Molecular Basis of Steroid Action in the Prostate.

Authors:  Yuan-Shan Zhu
Journal:  Cellscience       Date:  2005-04-28

2.  Male pseudohermaphroditism resulting from a novel mutation in the human steroid 5 alpha-reductase type 2 gene (SRD5A2).

Authors:  R Anwar; S G Gilbey; J P New; A F Markham
Journal:  Mol Pathol       Date:  1997-02

3.  Discovery of a novel hybrid from finasteride and epristeride as 5α-reductase inhibitor.

Authors:  Zhiyi Yao; Yingjun Xu; Minmin Zhang; Sheng Jiang; Marc C Nicklaus; Chenzhong Liao
Journal:  Bioorg Med Chem Lett       Date:  2010-10-28       Impact factor: 2.823

Review 4.  Endocrine and adrenergic pharmacological intervention in diseases of the prostate.

Authors:  A Rane
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

5.  Molecular genetics and phenotype/genotype correlation of 5-α reductase deficiency in a highly consanguineous population.

Authors:  Meshael M Alswailem; Ohoud S Alzahrani; Lamyaa Alghofaili; Ebtesam Qasem; Mai Almohanaa; Afaf Alsagheir; Bassam Bin Abbas; Najya A Attia; Adnan Al Shaikh; Ali S Alzahrani
Journal:  Endocrine       Date:  2018-09-29       Impact factor: 3.633

6.  5α-reductase type I expression is downregulated in the prefrontal cortex/Brodmann's area 9 (BA9) of depressed patients.

Authors:  Roberto Carlos Agis-Balboa; Alessandro Guidotti; Graziano Pinna
Journal:  Psychopharmacology (Berl)       Date:  2014-04-30       Impact factor: 4.530

7.  Molecular genetic analysis and human chorionic gonadotropin stimulation tests in the diagnosis of prepubertal patients with partial 5 alpha-reductase deficiency.

Authors:  O Hiort; H Willenbring; N Albers; W Hecker; J Engert; L Dibbelt; G H Sinnecker
Journal:  Eur J Pediatr       Date:  1996-06       Impact factor: 3.183

8.  SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.

Authors:  Christine Neslund-Dudas; Cathryn H Bock; Kristin Monaghan; Nora L Nock; James J Yang; Andrew Rundle; Deliang Tang; Benjamin A Rybicki
Journal:  Prostate       Date:  2007-11-01       Impact factor: 4.104

9.  Novel compound heterozygous mutations in the SRD5A2 gene from 46,XY infants with ambiguous external genitalia.

Authors:  Felipe Vilchis; Evangelina Valdez; Luis Ramos; Rocio García; Rita Gómez; Bertha Chávez
Journal:  J Hum Genet       Date:  2008-03-19       Impact factor: 3.172

10.  Semiquantitative RT-PCR method coupled to capillary electrophoresis to study 5alpha-reductase mRNA isozymes in rat ventral prostate in different androgen status.

Authors:  Jesus M Torres; José A Gómez-Capilla; Estrella Ruiz; Esperanza Ortega
Journal:  Mol Cell Biochem       Date:  2003-08       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.